Hematology-Oncology and Stem Cell Transplantation Unit, Istituto Nazionale Tumori, Fondazione 'G.Pascale', IRCCS, Naples.
Eur J Haematol. 2011 Dec;87(6):547-53. doi: 10.1111/j.1600-0609.2011.01683.x. Epub 2011 Jul 31.
Patients with recurring T-cell non-Hodgkin lymphoma (T-NHL) are incurable and candidate for investigational agents. Here, we report on five patients with T-NHL refractory to multiple chemotherapy lines, including in all cases alkylators and gemcitabine, who received the third-generation chloroethylnitrosourea fotemustine at a dose of 120 mg/m(2) every 21 d, up to eight courses. Median actual dose intensity was 79%; toxicity was manageable and mainly hematological. One complete remission, one partial remission, two protracted disease stabilization, and one transient, minor response were achieved. Time to progression ranged from 48 to 240+ d. This is the first evidence ever reporting the activity of fotemustine in end-stage T-NHL. Formal studies with this agent are warranted in T-cell malignancies.
复发的 T 细胞非霍奇金淋巴瘤（T-NHL）患者无法治愈，是研究药物的候选人群。在此，我们报告了 5 例 T-NHL 患者，他们对多种化疗方案均耐药，包括烷化剂和吉西他滨，这些患者接受第三代氯乙基亚硝脲福莫司汀，剂量为 120mg/m(2)，每 21d 一次，最多 8 个疗程。中位实际剂量强度为 79%；毒性可耐受，主要为血液学毒性。1 例完全缓解，1 例部分缓解，2 例疾病稳定时间延长，1 例短暂、轻微缓解。进展时间为 48-240+ d。这是首次报道福莫司汀在晚期 T-NHL 中的疗效。有必要对此类药物进行 T 细胞恶性肿瘤的正式研究。
